期刊文献+

黄芩素抗人巨细胞病毒的体外实验研究 被引量:4

Antiviral Effects of Baicalein on Human Cytomegalovirus in Vitro
下载PDF
导出
摘要 目的体外研究黄芩素抗人巨细胞病毒(human cytomegalovirus,HCMV)的效果和安全性。方法细胞病变法和噻唑蓝(MTT)法检测各浓度黄芩素对人胚肺成纤维细胞(HEL)存活率及HCMV抑制率的影响,并与更昔洛韦进行比较。数据输入SigmaPlot软件,经Hill方程曲线拟合计算药物的半数毒性浓度(TC50)和半数有效浓度(EC50)。结果更昔洛韦和黄芩素的TC50分别为353.1"g/ml和151.4"g/ml,EC50分别为62.98"g/ml和14.47"g/ml,治疗指数分别为6和10。结论黄芩素具有体外抗HCMV作用,值得进一步研究。 Objective To study the anti-cytomegalovirus effect and security of baicalein. Methods HEL ceil viability and HCMV inhibitory rate of baicalein in different dosage groups were detected with the cytopathic assay and MTT method,and ganciclovir was used as the control drug for comparison. All data input SigmaPlot statistical software for analyzing 50 % toxic concentrations (TC50) and 50% effective concentrations (EC50). Results The TC50 of ganciclovir and baicalein were 353.1 μg/ml and 151.4 μg/ml;the EC50 were 62.98 μg/ml and 14.47 μg/ml; TI were 6 and 10,respectively. Conclusion Baicalein has the potential advantages for clinical use and worth further study.
出处 《中西医结合研究》 2013年第1期13-16,20,共5页 Research of Integrated Traditional Chinese and Western Medicine
基金 国家自然科学基金资助项目(No:39970769 30371488 30672243) 湖北省自然科学基金资助项目(No:2009CDD216) 国家自然科学青年基金资助项目(No:81200354)
关键词 黄芩素 人巨细胞病毒 baicalein human cytomegalovirus
  • 相关文献

参考文献14

  • 1HYDE TB, SCHMID DS, CANNON MJ. Cytomegalovir- us seroconversion rates and risk factors: implications for congenital CMV[J]. Rev Med Virol, 2010, 20 (5) : 311- 326.
  • 2SCOTT GM, CHOW SS, CRAIG ME, et al. Cytomegalov irus infection during pregnancy with maternofetal trans mission induces a proinflammatory cytokine bias in pla- centa and amniotic fluid[J]. J Infect Dis, 2012, 205 (8) : 1305- 1310.
  • 3孙文英,孙新,肖华,魏超平,叶青青,李小晶,高伟玲.更昔洛韦治疗婴幼儿巨细胞病毒感染安全性和不良反应的临床研究[J].中国儿童保健杂志,2002,10(4):230-232. 被引量:32
  • 4张喜平,李宗芳,刘效恭.黄芩素的药理学研究概况[J].中国药理学通报,2001,17(6):711-713. 被引量:94
  • 5CORDIER AG, GUITTON S, VAULOUP-FELLOUS C, et al. Awareness of cytomegalovirus infection among pregnant women in France[J]. J Clin Virol, 2012,53 (4) .. 332-337.
  • 6ROSS SA, BOPPANA SB. Congenital cytomegalovirus in fection: outcome and diagnosis [J]. Semin Pediatr Infect Dis,2005,16(1) :44-49.
  • 7CANNON MJ,SCHMID DS, HYDE TB. Review of cyto- megalovirus seroprevalence and demographic characteris- tics associated with infection[J]. Rev Med Virol,2010,20 (4) :202-213.
  • 8KENNESON A, CANNON MJ. Review and meta-analy- sis of the epidemiology of congenital cytomegalovirus (CMV) infection[J]. Rev Med Virol,2007,17 (4) : 253- 276.
  • 9SIMIONI C,SANCHEN OLIVEIRA RD, MOSCOVI T, et al. Twin pregnancy and congenital cytomegalovirus: case report and review[J]. J Matern Fetal Neonatal Med, 2012. [Epub ahead of print].
  • 10SCHLEISS MR. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection[J]. J Pediatr, 2007,151 (6) :564-570.

二级参考文献57

  • 1吴明华,李维召.鸡新城疫免疫研究[J].畜牧兽医科技信息,2006,22(3):17-18. 被引量:18
  • 2钱生勇,金燕锋.HQS对大鼠实验性缺血损伤心肌的保护作用[J].甘肃中医学院学报,2007,24(2):15-17. 被引量:1
  • 3周新,李宏杰.黄酮类化合物的生物活性及临床应用进展[J].中国新药杂志,2007,16(5):350-355. 被引量:75
  • 4陈雯,张明昌,彭云,胡义珍.黄芩素对人眼球筋膜囊成纤维细胞增生的影响[J].眼科新进展,2007,27(6):436-439. 被引量:2
  • 5Dickenmann MJ,Kabulbayev K,Steiger J,et al.Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing antilymphocyte globulin treatment for acute rejection.Clin Microbiol Infect,2004,10(4):337-339.
  • 6Muller GA,Muller CA,Einsele H,et al.Cytomegalovirus infection:how to manage it in the immunocompromised transplant recipients.Nephrol Dial Transplant,1994,9(1):3-4.
  • 7Preiksaitis Jk,Brennan DC,Fishman J,et al.Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.Am J Transplant,2005,5(2):218-227.
  • 8Jung C,Engelmann E,Bomer K,et al.Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation.Transplant Proc,2001,33(7-8):3621-3623.
  • 9Kalil AC,Levitsky J,Lyden E,et al.Meta-analysis:the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.Ann Intern Med,2005,143(12):870-880.
  • 10Kalil AC,Levitsky J,Lyden E,et al.Meta-Analysis:The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.Ann Intern Med,2005,143(12):870-880.

共引文献192

同被引文献101

引证文献4

二级引证文献178

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部